Ming, Simon Wan YauHaughney, JohnRyan, DermotSmall, IainLavorini, FedericoPapi, AlbertoSingh, DaveHalpin, David M. G.Hurst, John R.Patel, ShishirOchel, MatthiasKocks, Janwillem W. H.Carter, VictoriaHardjojo, AntonyPrice, David2020-11-262020-11-262020-11-26Ming, S W Y, Haughney, J, Ryan, D, Small, I, Lavorini, F, Papi, A, Singh, D, Halpin, D M G, Hurst, J R, Patel, S, Ochel, M, Kocks, J W H, Carter, V, Hardjojo, A & Price, D 2020, 'A comparison of the real-life clinical effectiveness of the leading licensed ICS/LABA combination inhalers in the treatment for COPD', International journal of chronic obstructive pulmonary disease , vol. 15, pp. 3093-3103. https://doi.org/10.2147/COPD.S2637451176-9106https://hdl.handle.net/2164/15411Acknowledgment The authors extend their thanks to Dr. Kevin Gruffydd-Jones for his clinical and scientific input in the conduct and writing of this study. Dave Singh is supported by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre (BRC). Funding This study was funded by Chiesi Limited. The sponsor is involved in the design and presentation of the study.11607146engSDG 3 - Good Health and Well-beingMetered Dose InhalerDry Powder InhalerChronic Obstructive Pulmonary DiseaseTreatment efficacyCost effectivenessChronic obstructive pulmonary diseaseDry-powder inhalerMetered-dose inhalerCost-effectivenesscost-effectivenessPARTICLEmetered-dose inhalerFORMOTEROLBECLOMETHASONE/FORMOTEROLDISEASEEXACERBATIONSASTHMACORTICOSTEROIDSAIRWAYSdry-powder inhalerchronic obstructive pulmonary diseasetreatment efficacyR Medicine (General)Public Health, Environmental and Occupational HealthHealth PolicyPulmonary and Respiratory MedicineR1Journal article10.2147/COPD.S263745http://www.scopus.com/inward/record.url?scp=85097121484&partnerID=8YFLogxK15